Table 2 Primary Outcomes
Variable | Readmission Rates Including Unplanned Physician’s Clinic Visit | |||
|---|---|---|---|---|
Pharmacist-counseled n = 100 | Standard of care n = 100 | OR (95% CI) | P-value | |
Within 3 days | ||||
Follow-up 1 call completed | 92 | 91 | 0.621 | |
Patient called or had face-to-face contact with physician (unplanned contact) | 14 | 4 | 0.238 (0.075–0.754) | 0.010 |
Patient referred to urgent care | 2 | 0 | 0.369 | |
Patient readmitted (all-cause) | 0 | 0 | ||
Within 30 daysa | ||||
Follow-up 2 call completed | 100 | 97 | 0.246 | |
Patient had face-to-face contact with physician | 13 | 11 | 0.928 (0.484–2.453) | 0.883 |
Patient readmitted (all-cause) | 15 | 12 | 0.847 (0.380–1.886) | 0.802 |
Patient readmitted – related to anticoagulant use | 7 | 7 | 0.684 (0.193–2.419) | 0.650 |
Time to hospitalization (mean in days, +/− SD) | 16.9 +/− 9.8 | 21.7 +/− 7.1 | 0.197 | |
Bleeding Outcomes | ||||
Within 3 days | ||||
Follow-up 1 call completed | 92 | 91 | 0.621 | |
Bleeding within 3 days | 7 | 4 | 0.533 (0.151–1.888) | 0.483 |
Minor bleeding | 1 | 2 | 0.523 | |
Clinically relevant non-major bleeding | 5 | 2 | 0.333 | |
Major bleeding | 1 | 0 | 0.435 | |
Bleeding site (within 3 days) | ||||
Nose bleed | 1 | 2 | 0.693 | |
Gum bleed | 0 | 1 | 0.593 | |
Blood in sputum | 0 | 1 | 0.593 | |
Blood in stool | 2 | 1 | 0.574 | |
Black/dark stool | 1 | 1 | 0.975 | |
Blood in urine | 2 | 0 | 0.435 | |
Bruises | 1 | 0 | 0.435 | |
Within 30 daysa | ||||
Follow-up 2 call completed | 100 | 97 | 0.246 | |
Bleeding within 30 days | 14 | 17 | 1.161 (0.544–2.475) | 0.700 |
Apixaban | 2 | 1 | ||
Dabigatran | 1 | 3 | ||
Rivaroxaban | 8 | 6 | ||
Vitamin K antagonist | 3 | 7 | ||
Minor bleeding | 4 | 6 | 1.532 (0.419–5.603) | 0.124 |
Apixaban | 0 | 1 | ||
Dabigatran | 0 | 1 | ||
Rivaroxaban | 3 | 3 | ||
Vitamin K antagonist | 1 | 1 | ||
Clinically relevant non-major bleeding | 8 | 10 | 1.263 (0.329–4.848) | 0.136 |
Requiring medical intervention | 4 | 4 | 0.159 | |
Leading to hospitalization | 2 | 2 | 0.231 | |
Prompting a face to face evaluation | 2 | 4 | 0.121 | |
Major bleeding | 2 | 1 | 0.660 (0.108–4.036) | 0.115 |
Intracranial bleeding | 1 (Dabigatran) | 0 | 0.132 | |
Transfusion of more than 2 units of PRBCs | 1 (Apixaban) | 1 (Rivaroxaban) | 0.139 | |
Bleeding site | ||||
Nose bleed | 3 | 2 | 0.653 | |
Gum bleed | 1 | 2 | 0.369 | |
Blood in sputum | 0 | 2 | 0.369 | |
Blood in stool | 1 | 2 | 0.545 | |
Black/dark stool | 1 | 2 | 0.708 | |
Blood in urine | 2 | 1 | 0.291 | |
Blood vomitus | 1 | 0 | 0.459 | |
Bruises | 4 | 6 | 0.329 | |